THYROCARE558.00

Thyrocare Technologies Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersLALPATHLABMETROPOLISVIJAYASUPRIYAVIYASHSTARSPARCYATHARTHMcap ₹8,882 Cr
View
In ₹ Crore except Per Share
12 Months Ending
Q2 FY24
30/09/2023
Q3 FY24
31/12/2023
Q4 FY24
31/03/2024
Q1 FY25
30/06/2024
Q2 FY25
30/09/2024
Q3 FY25
31/12/2024
Q4 FY25
31/03/2025
Q1 FY26
30/06/2025
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
30/06/2026
Revenue from Operations148.0134.7154.3156.9177.4165.9187.2193.0216.5195.5224.0240.0
Other Income2.22.73.53.62.64.04.64.73.15.04.34.2
Total Income150.2137.5157.7160.5180.0169.9191.8197.7219.6200.5228.3244.2
Expenses
+ Cost of Materials Consumed43.138.046.144.750.144.848.755.459.847.156.461.9
+ Purchases of Stock-in-Trade0.40.71.10.11.30.20.50.10.20.00.80.0
+ Changes in Inventories0.2-0.3-0.60.8-0.40.20.30.20.00.1-0.50.3
+ Employee Benefit Expense27.126.426.628.729.535.133.533.033.235.836.139.6
+ Finance Costs1.11.11.11.00.80.60.70.80.6-0.11.51.4
+ Depreciation & Amortisation10.713.513.111.413.117.113.811.411.521.614.012.5
+ Other Expenses39.838.447.340.148.643.946.546.651.954.756.161.0
Total Expenses122.3117.7134.6126.6142.9141.9143.9147.5157.3159.2164.4176.6
EBITDA37.531.633.842.648.341.757.757.871.457.875.177.3
EBIT26.918.120.831.335.224.743.946.459.836.261.164.8
Profit
PBT before Exceptional Items27.919.823.133.937.128.147.850.262.341.363.967.6
+ Exceptional Items0.00.0-0.20.00.00.00.00.00.0-6.20.00.0
Pretax Income27.919.822.933.937.128.147.850.262.335.163.967.6
+ Current Tax8.85.47.110.0-12.311.014.314.317.010.016.118.5
+ Deferred Tax-0.9-0.2-1.4-0.42.0-2.111.3-2.1-2.2-2.6-0.3-1.5
Tax Expense7.95.25.79.6-10.49.025.612.214.87.315.717.0
+ Share of Associates & JVs0.40.10.0-0.4-0.3-0.2-0.60.30.30.30.60.7
Net Income20.314.717.223.947.119.021.638.347.828.148.751.3
+ Net Income — Continuing Ops20.014.617.224.347.419.122.238.047.527.848.150.6
+ Other Comprehensive Income0.10.00.1-0.5-0.1-0.0-0.2-0.20.1-0.10.70.4
Total Comprehensive Income20.414.717.223.547.118.921.338.147.927.949.451.7
Net Income to Common20.315.417.824.226.719.121.738.948.029.047.152.2
Minority Interest-0.0-0.6-0.6-0.2-0.2-0.2-0.1-0.6-0.2-1.01.6-0.9
Per Share
Basic EPS3.842.783.544.524.993.584.177.359.051.822.993.23
Diluted EPS3.842.773.544.514.983.564.167.339.031.812.983.22
Other Comprehensive Income — detail
+ Other Comprehensive Income-0.2-0.20.1-0.10.70.4
+ Items NOT to be Reclassified to P&L0.10.0-0.6-0.1-0.0-0.30.1-0.20.90.4
+ Tax on Items NOT to be Reclassified0.3-0.10.0-0.10.20.0
+ Tax on Items NOT to be Reclassified — alt tag0.00.0-0.1-0.2-0.0-0.0
+ Tax on Items to be Reclassified-0.10.0
+ Tax on Items to be Reclassified — alt tag0.00.00.0
Comprehensive Income — Owners of Parent20.415.417.323.726.619.121.538.748.128.947.852.6
Comprehensive Income — Non-controlling Interests-0.0-0.6-0.0-0.2-0.2-0.2-0.1-0.6-0.2-1.01.6-0.9
Per Share — as-filed variants
Basic EPS — Continuing Operations3.842.783.544.524.993.584.177.359.051.822.993.23
Diluted EPS — Continuing Operations3.842.773.544.514.983.564.167.339.031.812.983.22
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit104.496.3107.7111.5126.4120.8137.7137.4156.5148.3167.3177.9
Gross Margin %70.5171.4969.8171.0371.2572.7873.5771.1872.2675.8674.6974.10
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)27.919.823.133.937.128.147.850.262.341.363.967.6
− Exceptional Items (reconciliation)0.00.0-0.20.00.00.00.00.00.0-6.20.00.0
Net Income Adj (tax-effected)20.314.717.323.947.119.021.638.347.832.948.751.3
EPS Adj3.842.783.574.524.993.584.177.359.052.142.993.23
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value10.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.00
Filed Debt Equity0.000.000.000.000.00
Filed Dscr0.020.000.00
Filed Iscr0.490.000.00
Paid Up Equity Capital52.953.053.053.053.053.053.053.053.0159.2159.2159.2
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.